Corbion N.V. — Capital/Financing Update 2010

Sep 10, 2010

CSM nv Corporate Communications

Nienoord 13 1112 XE Diemen PO Box 349 1000 AH Amsterdam the Netherlands

Press Release Purac to build new plant for biomedical polymers

date September 10, 2010

CSM's subsidiary Purac announces that it will invest in a new manufacturing facility for its biomedical polymers. The plant is meant to support the growing resorbable polymers business of Purac Biomaterials. Purac currently operates a plant for biomedical polymers in The Netherlands. This second facility will be built in the USA. The investment for this new plant will be EUR 15 million. The construction of the facility will start in 2011 and is expected to be completed before the end of the year.

Gerard Hoetmer, CEO of CSM comments: "This represents an important step in the biomedical polymer business and shows Purac's continued commitment to this market. It provides us with the capability to support the growth of our existing and new business partners."

Besides an increase in the production capacity, the new facility will bring Purac Biomaterials more flexibility and a more balanced presence in its global markets.

The Purac Biomaterials business comprises Lactide based polymers such as Poly Lactic Acid (PLA) and Lactide/Glycolide Copolymers (PLGA). The technology as developed for Purac's biomedical polymers also formed the basis for Purac's activities in L- and D-Lactides for bioplastics such as Poly Lactic Acid (PLA).

For more information, please contact:

Press: Eva Lindner, Communication Director, Tel. +31 20 5906320 Analysts: Ian Blackford, Investor Relations Manager, Tel. +31 (0)20 5906349 / cell phone +44 (0)7767 227506

----------------------------------------------------------------------------------------------------------------------

Background information:

CSM is the largest supplier of bakery products worldwide and is global market leader in lactic acid and lactic acid derivatives. CSM produces and distributes an extensive range of bakery products and ingredients for artisan and industrial bakeries and for in-store as well as out-of-home markets. It also produces a variety of lactic acid applications for the food, chemical and pharmaceutical industries. CSM operates in business-to-business markets throughout Europe, North America, South America, and Asia, generates annual sales of € 3 billion and has a workforce of around 10,000 employees in 25 countries. CSM is listed on NYSE Euronext Amsterdam. For more information: www.csmglobal.com